Benzodiazepine use in medical cannabis authorization adult patients from 2013 to 2021: Alberta, Canada
Abstract Background: Benzodiazepines are a class of medications that are being frequently prescribed in Canada but carry significant risk of…
Dean T. Eurich
Metabolomic Fingerprint of Behavioral Changes in Response to Full-Spectrum Cannabis Extracts
Abstract Numerous existing full-spectrum cannabis extract products have been used in clinical trials for the treatment of various diseases. Despite…
Substance Use Disorders and Psychoactive Drug Poisoning in Medically Authorized Cannabis Patients: Longitudinal Cohort Study
Abstract Objectives: Poisoning from psychoactive drugs and substance use disorders (SUD) have been reported among non-medical cannabis users. However, little…
Medical cannabis authorization and the risk of cardiovascular events: a longitudinal cohort study
Abstract Background: Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed…
Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada
Abstract Background: With legal access to medical cannabis in Canada since 2001, there is a need to fully characterize its…
Opioid use in medical cannabis authorization adult patients from 2013 to 2018: Alberta, Canada
Abstract Background: The opioid overdose epidemic in Canada and the United States has become a public health crisis – with…
Cohort study of medical cannabis authorization and motor vehicle crash-related healthcare visits in 2014–2017 in Ontario, Canada
Abstract Background: With increasing numbers of countries/jurisdictions legalizing cannabis, cannabis impaired driving has become a serious public health concern. Despite…